Breast cancer chemoprevention
Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced by at least 50% with prophylactic agents. The current challenge is to find new agents which achieve this or better efficacy, but with fewer side effects. Recent results indic...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/130 |